Olanzapine/samidorphan

Last updated
Olanzapine/samidorphan
Combination of
Olanzapine Atypical antipsychotic
Samidorphan Opioid antagonist
Clinical data
Trade names Lybalvi
Other namesALKS-3831; OLZ/SAM
AHFS/Drugs.com Micromedex Detailed Consumer Information
MedlinePlus a621051
License data
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Olanzapine/samidorphan, sold under the brand name Lybalvi, is a fixed-dose combination medication for the treatment of schizophrenia and bipolar I disorder. [1] It contains olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist. [1] [2] [3] Samidorphan reduces the weight gain associated with olanzapine while still allowing olanzapine to exert its therapeutic effect. [4] [5] Although Lybalvi still produces transient weight gain of roughly 7 pounds, its metabolic profile is significantly lower than olanzapine alone, as the latter triggers around 50-100 pounds following long-term use. The formulation was approved for medical use in the United States in May 2021. [1] [6]

References

  1. 1 2 3 4 "Lybalvi- olanzapine and samidorphan l-malate tablet, film coated". DailyMed. 24 February 2022. Retrieved 1 May 2023.
  2. ↑ Maric NP, Jovicic MJ, Mihaljevic M, Miljevic C (2016). "Improving Current Treatments for Schizophrenia". Drug Development Research. 77 (7): 357–367. doi:10.1002/ddr.21337. PMID   27633376. S2CID   205750190.
  3. ↑ Fellner C (2017). "New Schizophrenia Treatments Address Unmet Clinical Needs". P T. 42 (2): 130–134. PMC   5265239 . PMID   28163559.
  4. ↑ Citrome L, Graham C, Simmons A, Jiang Y, Todtenkopf MS, Silverman B, et al. (2021). "An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder". Neuropsychiatr Dis Treat. 17: 2885–2904. doi: 10.2147/NDT.S313840 . PMC   8437420 . PMID   34526769.
  5. ↑ Paik J (August 2021). "Olanzapine/Samidorphan: First Approval". Drugs. 81 (12): 1431–1436. doi:10.1007/s40265-021-01568-0. PMID   34304374. S2CID   236215923.
  6. ↑ "Drug Approval Package: Lybalvi". U.S. Food and Drug Administration (FDA). 26 June 2021. Retrieved 12 September 2021.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.